SWK (SWKH) Q3 2024 earnings summary

Executive summary

• Core business focuses on financing commercial-stage life science companies via first lien term loans and royalties, targeting $5–$25 million investments in an underserved market segment.

• Q3 2024 revenue increased to $10.4 million, up $1.4 million year-over-year, driven by higher finance receivables and pharmaceutical development income.

• Net income for Q3 2024 was $3.5 million, down from $4.5 million in Q3 2023, primarily due to higher credit loss provisions and interest expense.

• Portfolio is expected to approach an all-time high by year-end, driven by new deals and unfunded commitments being drawn.

• Significant progress made on resolving non-accrual loans post-quarter, expected to improve return on capital.

Financial highlights

• Core finance segment generated $5 million of adjusted non-GAAP net income in Q3 2024.

• Gross finance receivables portfolio increased 15% year-over-year to $270 million.

• Segment revenue rose 13.5% year-over-year to approximately $2 million, with a 13.8% realized yield.

• Q3 2024 provision for credit losses was $1.4 million, up from $0.2 million in Q3 2023, reflecting impairments on specific loans.

• Interest expense increased to $1.1 million in Q3 2024, mainly due to the issuance of $32.9 million in 9.00% Senior Notes due 2027.

Outlook and guidance

• Anticipates closing an $8 million term loan and advancing additional capital to existing borrowers by year-end.

• Expects realized yield to revert to or exceed effective yield as non-accruals are resolved.

• Targeting 10% growth in tangible book value per share in 2025 and beyond.

• Management expects the finance receivables portfolio and pharmaceutical development segment to generate positive cash flows in 2024.

• The company continues to evaluate new investment opportunities but does not assume near-term repayments from borrowers.